Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety

Table 3 Immunophenotype assessment in different therapy group

T cell	No. of trials	No. of patients		MD	95% CI	p value
		Non-CIK	CIK
CD3⁺	6	276	162	-0.79	-1.13 to -0.45	< 0.001
CD4⁺	5	258	150	-2.00	-2.70 to -1.3	< 0.001
CD8⁺	5	258	150	3.05	2.43 to 3.67	< 0.001
CD3⁺ CD8⁺	2	57	54	-1.83	-2.10 to -1.56	< 0.001
CD4⁺ CD8⁺	6	285	188	0.04	0.03 to 0.05	< 0.001
CD3⁺ CD4⁺	2	57	54	-2.02	-2.27 to -1.76	< 0.001

Summary differences of immunophenotype assessment in different therapy group were calculated using the fix-effects model. To assess statistical heterogeneity between studies, the Cochran Q test was performed, with a predefined significance threshold of 0.1.
Note: CIK CIK-containing therapy; CI confidence interval; MD mean difference

ISSN: 2162-3619